|
NR. 3(II)/2009
|
|
|
|
|
|
|
|
|
Leczenie
neowaskularyzacji podsiatkówkowej w przebiegu zwyrodnienia
plamki związanego z wiekiem w Klinice Chorób Oczu w Bydgoszczy w
latach 2006-2008
Subretinal Neovascularization Treatment Due to Age-related
Macular Degeneration in Ophthalmology Department of the
Collegium Medicum in Bydgoszcz Since 2006 to 2008
Magdalena Grześk, Małgorzata
Seredyka-Burduk, Józef Kałużny
Katedra i Klinika Chorób Oczu Uniwersytetu im. Mikołaja
Kopernika w Toruniu
Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy
Kierownik: prof. dr hab. n. med. Józef Kałużny |
|
|
|
|
|
|
|
| Summary: |
Introduction:
Subretinal neovascularization due to age-related macular
degeneration is the most common reason of irreversible
blindness in patients aged fifty. With becoming older
the risk of the retinal degeneration increase. Taking
under consideration fact, that societies became older,
people lifetime became longer and longer, every day
there is more and more people who should be treated. The
most common risk factors of age-related macular
degeneration seems to be cardio-vascular diseases,
diabetes and smoking. Vascular endothelial growth factor
is thought to play very important role in subretinal
neovascularization etiology.
Purpose: To compare results of intravitreal
pegaptanib injection versus photodynamic injection with
verteporfirin as a primary treatment of subretinal
neovasularization due to age-related macular
degeneration.
Material and method: The eyes were assigned to
the group treated with the use of the PDT or
intravitreal pegaptanib injection. The treatment was
established up to the type of the degeneration. We
treated 97 patients with AMD. Photodynamic therapy were
made in 65 patients (74 eyes) (group I), 32 patients (43
eyes) were given intravitreal pegaptanib injections (group
II). We have made 205 PDT (on average 2.76 ± 2.35) and
176 intravitreal injections (on average 5.18 ± 2.55).
The most of the patients were women. VA before treatment
were on average 0.35 ± 0.21 (0.04 to 0.9) in I group and
in II group 0.42 ± 0.23 (0.1 to 1,0). After treatment VA
decreased in both I and II group and were 0.30 ± 0.22
(0.02 to 0.9) in I group and 0.37 ± 0.27 (0.1 to 1.0) in
II group.
Conclusions: In most cases there were clinical
stabilization, in spite of the fact that in fluorescein
angiography diameter of the retinal damage increased.
Both patients and their patients are waiting for new,
safe medicine, which diminish the risk of the vision
loss. |
| Key words: |
choroidal
neovascularization – CNV, age-related macular
degeneration – AMD. |
| Słowa kluczowe: |
neowaskularyzacja
podsiatkówkowa – CNV, zwyrodnienie plamki związane z
wiekiem – AMD. |
|
|
|
|
|
|
|
|
